Cannabis Science Inc (OTCMKTS:CBIS) has joined hands with IBX Bio Inc. to start an FDA passed clinical trial which will research the therapeutic use of the drug combination of CS-TATI-1 and GenePro®.
CS-TATI-1, which is a cannabinoid based drug, belongs to the product pipeline of Cannabis whereas GenePro® is the prime drug candidate of the biotech entity IBX Bio Inc. The biotech company has developed constructs of DNA of non-infectious HIV. The expert team believes that it can result in antibodies. The teaming up of two entities is historic and will improve the synergistic impact of CBDs and advanced HIV immunotherapy.
The extensive research validates that CBD has the potential to reduce inflammation and can even stop HIV replication. Both the problems are linked to each other as HIV results in inflammation, irrespective of its levels. Cannabis Science calls CBDs as the “missing puzzle piece” that will complete final picture of GenePro®.
The expert speaks
Mr. Raymond C. Dabne who is the President of Cannabis Science reported that the collaboration with IGX Bio is done to help attain new insights into the problem of inflammation. The process will help the companies to get closer to effective therapies for AIDS patients in distinct resource settings.
These new studies will give a scientific assessment of CS-TATI-1 and GenePro® to know the increased potential of the anti-inflammatory features of CBDs and get a therapeutic to deter disease advancement in AID patients. In addition to CS-TATI-1, the company is has two more drugs in development process. The plan of study is to slow down HIV replication without any harsh side effects.
In last trading session, the stock price of Cannabis Science Inc (OTCMKTS:CBIS) surged over 3% to close the trading session at $0.0214. The gains came at a share volume of 6.49 million compared to average share volume of 3.39 million.